

April W Armstrong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5694455/publications.pdf>

Version: 2024-02-01

206
papers

13,342
citations

31902

53
h-index

26548

107
g-index

220
all docs

220
docs citations

220
times ranked

10201
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. JAMA - Journal of the American Medical Association, 2020, 323, 1945.	3.8	953
2	Psoriasis. Lancet, The, 2021, 397, 1301-1315.	6.3	792
3	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	2.9	726
4	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine, 2015, 373, 1318-1328.	13.9	656
5	Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 2014, 70, 512-516.	0.6	650
6	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatorâ€“controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2017, 76, 418-431.	0.6	554
7	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine, 2016, 375, 422-434.	13.9	530
8	Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. Journal of the American Academy of Dermatology, 2013, 68, 654-662.	0.6	327
9	Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States. JAMA Dermatology, 2013, 149, 1180.	2.0	327
10	Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Metaâ€“Analysis of Observational Studies. Journal of the American Heart Association, 2013, 2, e000062.	1.6	324
11	Psoriasis and the Risk of Diabetes Mellitus. JAMA Dermatology, 2013, 149, 84.	2.0	262
12	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, The, 2019, 394, 831-839.	6.3	250
13	Videos to influence: a systematic review of effectiveness of video-based education in modifying health behaviors. Journal of Behavioral Medicine, 2014, 37, 218-233.	1.1	246
14	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 411.	2.0	241
15	Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003â€“2011. PLoS ONE, 2012, 7, e52935.	1.1	235
16	Psoriasis and smoking: a systematic review and metaâ€“analysis. British Journal of Dermatology, 2014, 170, 304-314.	1.4	199
17	The association between psoriasis and hypertension. Journal of Hypertension, 2013, 31, 433-443.	0.3	175
18	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. American Journal of Clinical Dermatology, 2016, 17, 87-97.	3.3	173

#	ARTICLE	IF	CITATIONS
19	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	2.0	169
20	Antidrug antibodies in psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2014, 170, 261-273.	1.4	143
21	Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. <i>Journal of Dermatological Science</i> , 2011, 63, 1-9.	1.0	140
22	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	6.3	139
23	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	0.6	137
24	The association between psoriasis and dyslipidaemia: a systematic review. <i>British Journal of Dermatology</i> , 2013, 168, 486-495.	1.4	130
25	Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985-2010. <i>PLoS ONE</i> , 2011, 6, e17520.	1.1	129
26	Psoriasis and suicidality: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 425-440.e2.	0.6	117
27	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007394.	1.3	115
28	A tale of two plaques: convergent mechanisms of T cell-mediated inflammation in psoriasis and atherosclerosis. <i>Experimental Dermatology</i> , 2011, 20, 544-549.	1.4	114
29	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2018, 154, 934.	2.0	112
30	Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. <i>British Journal of Dermatology</i> , 2011, 165, 1162-1168.	1.4	110
31	JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	0.9	102
32	Effects of video-based, online education on behavioral and knowledge outcomes in sunscreen use: A randomized controlled trial. <i>Patient Education and Counseling</i> , 2011, 83, 273-277.	1.0	97
33	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 2219-2229.	13.9	93
34	Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy. <i>PLoS ONE</i> , 2012, 7, e33486.	1.1	92
35	Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography. <i>American Journal of Cardiology</i> , 2012, 109, 976-980.	0.7	90
36	Online video improves clinical outcomes in adults with atopic dermatitis: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 502-507.	0.6	89

#	ARTICLE	IF	CITATIONS
37	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2â€”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	0.6	88
38	Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. <i>Archives of Dermatological Research</i> , 2018, 310, 271-319.	1.1	84
39	State of teledermatology programs in the United States. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 939-944.	0.6	81
40	Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 513-528.	0.9	80
41	An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. <i>PLoS ONE</i> , 2017, 12, e0181039.	1.1	79
42	Psoriasis and Hypertension Severity: Results from a Case-Control Study. <i>PLoS ONE</i> , 2011, 6, e18227.	1.1	78
43	Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. <i>Dermatology</i> , 2012, 225, 121-126.	0.9	77
44	Practice Models and Challenges in Teledermatology: A Study of Collective Experiences from Teledermatologists. <i>PLoS ONE</i> , 2011, 6, e28687.	1.1	73
45	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	1.1	72
46	Maintenance of clinical response and consistent safety profile with up to 3Âyears of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
47	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	0.6	69
48	The global burden of psoriatic skin disease. <i>British Journal of Dermatology</i> , 2015, 172, 1665-1668.	1.4	64
49	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020, 140, 1784-1793.e2.	0.3	61
50	Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. <i>Journal of Dermatological Treatment</i> , 2014, 25, 401-408.	1.1	59
51	Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. <i>Dermatologic Clinics</i> , 2012, 30, 113-124.	1.0	58
52	Safety of guselkumab in patients with moderateâ€toâ€severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <sc>VOYAGE</sc> 1 and <sc>VOYAGE</sc> 2 studies. <i>British Journal of Dermatology</i> , 2019, 180, 1039-1049.	1.4	57
53	Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 949-958.	1.3	56
54	Effect of tonsillectomy on psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 261-275.	0.6	56

#	ARTICLE	IF	CITATIONS
55	Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1093-1104.	1.6	55
56	Antibiotic Resistance in Acne Treatment. <i>JAMA Dermatology</i> , 2017, 153, 810.	2.0	54
57	Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 665-669.	0.6	51
58	Does class attendance matter? Results from a second-year medical school dermatology cohort study. <i>International Journal of Dermatology</i> , 2015, 54, 807-816.	0.5	51
59	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. <i>Rheumatology International</i> , 2017, 37, 97-105.	1.5	48
60	RAC1 activation drives pathologic interactions between the epidermis and immune cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 2661-2677.	3.9	48
61	Portable video media for presenting informed consent and wound care instructions for skin biopsies: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2010, 163, 1014-1019.	1.4	47
62	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 661.	2.0	46
63	Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 906-917.	0.6	45
64	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 968-977.e2.	0.6	43
65	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43
66	Standardizing Training for Psoriasis Measures. <i>JAMA Dermatology</i> , 2013, 149, 577.	2.0	42
67	Dermatologists in social media: A study on top influencers, posts, and user engagement. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1452-1455.	0.6	42
68	Teledermatology Operational Considerations, Challenges, and Benefits: The Referring Providers' Perspective. <i>Telemedicine Journal and E-Health</i> , 2012, 18, 580-584.	1.6	41
69	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	2.0	41
70	Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 500-512.	0.9	41
71	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	1.4	40
72	A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 329-336.	3.3	39

#	ARTICLE	IF	CITATIONS
73	Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1037-1044.	0.3	37
74	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 155-164.	3.3	37
75	Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 395-402.	0.6	36
76	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	0.6	36
77	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019, 181, 967-975.	1.4	34
78	Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (<scp>NHANES</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1109-1112.	1.3	33
79	Relationship between psoriasis and metabolic syndrome: a systematic review. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 663-677.	0.8	31
80	Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 383-391.e1.	0.6	30
81	Evaluation and Comparison of Store-and-Forward Teledermatology Applications. <i>Telemedicine Journal and E-Health</i> , 2010, 16, 424-438.	1.6	29
82	A Review of Health Outcomes in Patients with Psoriasis. <i>Dermatologic Clinics</i> , 2012, 30, 61-72.	1.0	28
83	From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 798-805.e7.	0.6	28
84	Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1325-1333.	0.9	27
85	Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1312-1316.	1.3	26
86	Public perception of dermatologists and comparison with other medical specialties: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 875-881.	0.6	26
87	Harnessing the Power of Crowds. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 405-416.	3.3	25
88	Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group. <i>Journal of Rheumatology</i> , 2014, 41, 2306-2314.	1.0	25
89	Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 691-699.	3.3	25
90	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <i>BMC Dermatology</i> , 2018, 18, 4.	2.1	24

#	ARTICLE	IF	CITATIONS
91	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	3.3	24
92	Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1181-1196.	1.4	24
93	Diet and nutrition in psoriasis: analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 327-332.	1.3	23
94	Do TNF Inhibitors Reduce the Risk of Myocardial Infarction in Psoriasis Patients?. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2043.	3.8	22
95	Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. <i>PLoS ONE</i> , 2019, 14, e0210517.	1.1	22
96	Long-Term Benefit/Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 167-184.	1.4	22
97	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 79-86.	3.3	21
98	Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. <i>RMD Open</i> , 2019, 5, e000867.	1.8	21
99	Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 740-746.	0.6	20
100	Characteristics of Medical Liability Claims Against Dermatologists From 1991 Through 2015. <i>JAMA Dermatology</i> , 2018, 154, 160.	2.0	20
101	Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>American Journal of Clinical Dermatology</i> , 2018, 19, 879-886.	3.3	20
102	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , 2019, 30, 27-34.	1.1	20
103	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 748-757.	0.6	20
104	Misconceptions of photoprotection in skin of color. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, S9-S17.	0.6	20
105	Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, S1-S8.	0.6	20
106	Why Some Dermatologists Do Not Practice Store-and-Forward Teledermatology. <i>Archives of Dermatology</i> , 2012, 148, 649-50.	1.7	18
107	Power of crowdsourcing: Novel methods of data collection in psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1273-1281.e9.	0.6	18
108	Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678.	1.0	18

#	ARTICLE	IF	CITATIONS
109	Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 91-97.	1.6	18
110	Psoriasis and Sexual Behavior in Men: Examination of the National Health and Nutrition Examination Survey (NHANES) in the United States. <i>Journal of Sexual Medicine</i> , 2014, 11, 401-410.	0.3	17
111	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	1.1	17
112	Managing Patients With Psoriasis in the Busy Clinic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 196-206.	0.6	16
113	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , 2013, 305, 891-897.	1.1	15
114	Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. <i>Clinical Drug Investigation</i> , 2017, 37, 493-501.	1.1	15
115	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 454-460.	1.1	15
116	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 1-11.	3.3	15
117	Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. <i>JAMA Dermatology</i> , 2022, 158, 252.	2.0	15
118	Psoriasis and Sexual Behavior in U.S. Women: An Epidemiologic Analysis Using the National Health and Nutrition Examination Survey (NHANES). <i>Journal of Sexual Medicine</i> , 2013, 10, 326-332.	0.3	14
119	Are patients comprehending? A critical assessment of online patient educational materials. <i>Journal of Dermatological Treatment</i> , 2018, 29, 295-299.	1.1	14
120	Economic burden of cutaneous infections in children and adults with atopic dermatitis. <i>Pediatric Dermatology</i> , 2019, 36, 303-310.	0.5	14
121	An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis. <i>Current Medicinal Chemistry</i> , 2015, 22, 1930-1942.	1.2	14
122	Comparative Prevalence of Complementary and Alternative Medicine Use Among Outpatients in Dermatology and Primary Care Clinics. <i>JAMA Dermatology</i> , 2014, 150, 1363.	2.0	13
123	Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. <i>Journal of Dermatological Treatment</i> , 2018, 29, 329-333.	1.1	13
124	Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey. <i>Dermatology and Therapy</i> , 2022, 12, 1055-1064.	1.4	13
125	Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 200-205.	1.1	12
126	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930.	0.6	11

#	ARTICLE	IF	CITATIONS
127	Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021, 32, 455-459.	1.1	11
128	Economic Burden of Chronic Hand Eczema: A Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 287-300.	3.3	11
129	The global burden of disease associated with alopecia areata. <i>British Journal of Dermatology</i> , 2015, 172, 1424-1426.	1.4	10
130	Perceptions of Aesthetic Outcome of Linear vs Multiple Z-Plasty Scars in a National Survey. <i>JAMA Facial Plastic Surgery</i> , 2016, 18, 263-267.	2.2	10
131	Using qualitative methods to understand factors contributing to patient satisfaction among dermatology patients: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 290-294.	1.1	10
132	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	0.9	10
133	Dermal suture only versus layered closure: A randomized, split wound comparative effectiveness trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1346-1352.	0.6	10
134	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	1.1	10
135	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	1.0	9
136	Quality of life among dermatology patients: a systematic review of investigations using qualitative methods. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 72-78.	0.8	9
137	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740.	1.4	9
138	Updates in Rosacea: Epidemiology, Risk Factors, and Management Strategies. <i>Current Dermatology Reports</i> , 2014, 3, 23-28.	1.1	8
139	Effectiveness of a novel interactive health care education tool on clinical outcomes and quality of life in acne patients: A randomized controlled pilot study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 435-439.	1.1	8
140	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960.	1.0	8
141	Development and psychometric evaluation of the self-assessment of psoriasis symptoms (SAPS) â€“ clinical trial and the SAPS â€“ real world patient-reported outcomes. <i>Journal of Dermatological Treatment</i> , 2017, 28, 505-514.	1.1	8
142	Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, , 1-4.	1.1	8
143	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828.	0.6	7
144	Suicidality among psoriasis patients: a critical evidence synthesis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 56-63.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey. <i>Advances in Therapy</i> , 2022, 39, 2657-2667.	1.3	7
146	Crowdsourcing for data collection: a pilot study comparing patient-reported experiences and clinical trial data for the treatment of seborrheic dermatitis. <i>Skin Research and Technology</i> , 2013, 19, 55-57.	0.8	6
147	Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial. <i>Dermatology and Therapy</i> , 2016, 6, 675-681.	1.4	6
148	Reply to: "Comment on "Dermatologists in social media: A study on top influencers, posts, and user engagement". <i>Journal of the American Academy of Dermatology</i> , 2022, 86, e51.	0.6	6
149	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022, 12, 787-800.	1.4	6
150	Economics of Teledermatology "Does the Math Add Up?. <i>JAMA Dermatology</i> , 2021, 157, 27.	2.0	5
151	Anogenital warts and relationship to child sexual abuse: Systematic review and meta-analysis. <i>Pediatric Dermatology</i> , 2021, 38, 842-850.	0.5	5
152	Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records. <i>Dermatology and Therapy</i> , 2021, 11, 1733-1749.	1.4	5
153	Bullous Dermatoses and Depression. <i>JAMA Dermatology</i> , 2021, 157, 1487.	2.0	5
154	Novel approach to utilizing electronic health records for dermatologic research: developing a multi-institutional federated data network for clinical and translational research in psoriasis and psoriatic arthritis. <i>Dermatology Online Journal</i> , 2012, 18, 2.	0.2	5
155	Development of a core outcome set for basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 573-581.	0.6	5
156	Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , 2020, 31, 452-459.	1.1	4
157	An association between hidradenitis suppurativa and HIV. <i>British Journal of Dermatology</i> , 2020, 182, 490-491.	1.4	4
158	Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians. <i>JAMA Dermatology</i> , 2020, 156, 754.	2.0	4
159	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2022, 238, 430-437.	0.9	4
160	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157.	1.4	4
161	Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. <i>Dermatology Online Journal</i> , 2015, 21, .	0.2	4
162	Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. <i>Dermatology Online Journal</i> , 2020, 26, .	0.2	4

#	ARTICLE	IF	CITATIONS
163	Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. <i>Dermatology and Therapy</i> , 2022, 12, 195-202.	1.4	4
164	Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologistsâ€™ Perspective: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2204-2210.	1.0	3
165	Patient-Centered Outcomes in Dermatology. <i>Current Dermatology Reports</i> , 2015, 4, 15-19.	1.1	3
166	Wound eversion versus planar closure for wounds on the face or neck: A randomized split-wound comparative effectiveness trial. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1439-1440.	0.6	3
167	Words matter: a randomized controlled study evaluating the impact of decisionâ€™ framing on treatment preferences in adults with psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , 2021, 184, 971-973.	1.4	3
168	Mental health outcomes and their association to race and ethnicity in acne patients: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 140-142.	0.6	3
169	Mental health outcomes in White patients versus patients with skin of color with psoriasis. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	3
170	Comparing the Effectiveness of Automated Online Counseling to Standard Web-Based Education on Improving Acne Knowledge: A Randomized Controlled Trial. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 55-60.	3.3	2
171	Association of Touch Avoidance with Disease Severity and Quality of Life in Psoriasis Patients. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 57-63.	0.3	2
172	Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 330-336.	0.6	2
173	Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <i>Archives of Dermatological Research</i> , 2019, 311, 453-460.	1.1	2
174	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 133-142.	0.3	2
175	Language proficiency and biologics access: a population study of psoriasis patients in the United States. <i>Journal of Dermatological Treatment</i> , 2020, , 1-5.	1.1	2
176	Response to Letter to the Editor â€™Reply to â€™ Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagementâ€™ Dermatologist Influencers on TikTokâ€™. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	2
177	Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 40-43.	1.0	2
178	Oral small molecules for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 163-166.	1.6	2
179	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 28-32.	1.0	2
180	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	0.9	1

#	ARTICLE	IF	CITATIONS
181	Exploring Mental Disorders in Patients With Skin Diseases. <i>JAMA Dermatology</i> , 2019, 155, 660.	2.0	1
182	Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 129-138.	0.3	1
183	GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations. <i>Journal of Rheumatology</i> , 2021, , jrheum.201670.	1.0	1
184	Differences in acne therapy prescribing patterns between dermatologists and pediatricians: A population-based study. <i>Pediatric Dermatology</i> , 2021, 38, 1150-1156.	0.5	1
185	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. <i>Journal of Medical Internet Research</i> , 2021, 23, e29511.	2.1	1
186	Chronic spontaneous urticaria: a 16-year analysis of pediatric patient demographics, treatment patterns, and comorbidities. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	1
187	Topical opioid use in dermatologic disease: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e15150.	0.8	1
188	Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. <i>Journal of Dermatological Treatment</i> , 0, , 1-9.	1.1	1
189	Innovations in teledermatology: direct patient "specialist care enabled by mobile technology. <i>Expert Review of Dermatology</i> , 2012, 7, 223-225.	0.3	0
190	Response to: "œls tonsillectomy a therapeutic option for plaque-type psoriasis?" <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e155.	0.6	0
191	Screening Recommendations for Hepatitis B Virus Infection. <i>JAMA Dermatology</i> , 2016, 152, 565.	2.0	0
192	Response to Letter to the Editor commenting on: "œ Dermatologists in social media: A study on top influencers, posts, and user engagement" <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e165.	0.6	0
193	Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. <i>Journal of Dermatological Treatment</i> , 2021, , 1-3.	1.1	0
194	Childhood atopic dermatitis: outpatient visit trends, demographics, and topical agents in the United States, 1995-2015. <i>International Journal of Dermatology</i> , 2021, 60, e423-e424.	0.5	0
195	Non-Medical Switching Impact on Patients and Providers " Psoriatic Disease Community Taking a Stand. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 126-127.	0.3	0
196	Opiate use in dermatology: A population-based study using the National Ambulatory Medical Care Survey in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 174-176.	0.6	0
197	Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	0
198	Trichotillomania in the United States: An epidemiologic study of patient characteristics, comorbidities, and treatment patterns. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	0

#	ARTICLE	IF	CITATIONS
199	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. Journal of Investigative Dermatology, 2021, 141, 2539-2541.	0.3	0
200	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4.	0.3	0
201	Re-Classification of Psoriasis Severity: Perspectives and Controversy. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 7-8.	0.3	0
202	Are we contributing to the opioid epidemic? A systematic review on systemic opioid use in dermatology. International Journal of Dermatology, 2021, , .	0.5	0
203	2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations. Journal of Rheumatology, 2022, , jrheum.211318.	1.0	0
204	The psoriasis glycome: differential expression of cholesterol particle glycans and IgA glycans linked to disease severity. Journal of Investigative Dermatology, 2022, , .	0.3	0
205	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , .	1.0	0
206	Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032211100.	0.3	0